Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company developing targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs include latiglutenase for celiac disease, capeserod for various GI conditions, and adrulipase for aiding fat digestion in cystic fibrosis and chronic pancreatitis patients. The company also plans to develop Niclosamide for treating ulcerative proctitis, ulcerative proctosigmoiditis, and immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. We show 6 historical shares outstanding datapoints in our ENTO shares outstanding history coverage, used to compute ENTO market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ENTO market cap history over the course of time is important for investors
interested in comparing ENTO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ENTO versus a peer is one thing; comparing
ENTO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ENTO can fluctuate over the course of history.
With this page we aim to empower investors researching ENTO by allowing them to research the ENTO market cap history. |
Free ENTO Email Alerts:
Video: The Importance of Market Cap
